Pasithea Therapeutics Corp.

Pasithea Therapeutics announced that an abstract detailing its Phase 1 dose-escalation study of PAS-004 has been accepted for a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026. The presentation will occur on October 23, 2026, and will cover the safety and pharmacokinetics of PAS-004, a macrocyclic MEK inhibitor, for patients with MAPK pathway-driven advanced solid tumors. The full abstract will be published on the ESMO website, and the company intends to release detailed results concurrently with the presentation.

Pasithea Therapeutics Corp. announced that its management will participate in the Mind, Muscle & Vision Summit, hosted by B. Riley Securities, on July 16, 2026. The company's management will be available for one-on-one meetings with institutional investors and other conference participants. Pasithea is a clinical-stage biotechnology company focused on developing PAS-004, a MEK inhibitor, currently in Phase 1 clinical trials for advanced cancer and Phase 1/1b trials for neurofibromatosis type 1.

Pasithea Therapeutics Corp. announced its participation as an exhibitor at the Children's Tumor Foundation (CTF) 2026 NF Conference in Denver, Colorado, from June 26-30, 2026. The company aims to engage directly with the NF1 community regarding its lead treatment candidate, PAS-004, a next-generation macrocyclic MEK inhibitor. This follows recent FDA Fast Track and Rare Pediatric Disease Designations for PAS-004, which is currently in Phase 1 clinical trials for advanced cancer and NF1-associated plexiform neurofibromas.

Pasithea Therapeutics Corp. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead drug candidate, PAS-004, for the treatment of Amyotrophic Lateral Sclerosis (ALS). This designation provides potential benefits including tax credits for clinical trials, exemption from certain FDA fees, and seven years of market exclusivity upon approval. The company previously received a $1 million grant from the ALS Association to study PAS-004 for ALS.

Pasithea Therapeutics Corp. reported a reduced net loss of $(2.87) million for Q1 2026, an improvement from $(3.56) million in Q1 2025, with basic and diluted loss per share improving to $(0.12) from $(1.61). This improvement occurred despite a 70% increase in research and development expenses to $2.94 million and higher net cash used in operating activities, which reached $(4.79) million. The company ended the quarter with $50.4 million in cash and cash equivalents and continues to advance its PAS-004 clinical trials, including completing initial cohorts for its advanced cancer study and initiating a Phase 1/1b trial for NF1 patients.

Pasithea Therapeutics Corp. announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer, effective May 1, 2026. Dr. Krishnan will lead all clinical development and medical strategy for the company's lead drug candidate, PAS-004, a next-generation MEK inhibitor for neurofibromatosis type 1. His extensive experience, including the development of the FDA-approved MEK inhibitor cobimetinib, is expected to significantly advance the PAS-004 program.